TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in respiratory disorders, announced the presentation of preclinical results from its research program in chronic obstructive pulmonary disease (COPD). These results have been accepted for poster presentations at the upcoming American Thoracic Society International Conference in San Diego, CA.
